Journal of Neuroimmunology
Volume 220, Issue 1 , Pages 1-9 , 30 March 2010

Herpes simplex type I (HSV-1) infection of the nervous system: Is an immune response a good thing?

  • Christopher D. Conrady

      Affiliations

    • Department of Microbiology, Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States
    • ,
  • Douglas A. Drevets

      Affiliations

    • Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States
    • Veterans Affairs Medical Center, Oklahoma City, OK, 73104, United States
    • ,
  • Daniel J.J. Carr

      Affiliations

    • Department of Microbiology, Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States
    • Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States
    • Corresponding Author InformationCorresponding author. Department of Microbiology, Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States.

Received 1 September 2009 ,Revised 15 September 2009 ,Accepted 15 September 2009.

References 

  1. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296:1653–1655
  2. Ahmad R, El Bassam S, Cordeiro P, Menezes J. Requirement of TLR2-mediated signaling for the induction of IL-15 gene expression in human monocytic cells by HSV-1. Blood. 2008;112:2360–2368
  3. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 2003;85:85–95
  4. Akira S, Takeda K. Toll-like receptor signaling. Nat. Rev. Immunol. 2004;4:499–511
  5. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001;2:675–680
  6. Akira S, Uematsu S, Takeuchi O. Cell. 2006;124:783–801
  7. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature. 2001;413:732–738
  8. Anglen CS, Truckenmiller ME, Schell TD, Bonneau RH. The dual role of CD8+ lymphocytes in the development of stress-induced herpes simplex encephalitis. J. Neuroimmunol. 2003;140:13–27
  9. Baker M, Noisakran S, Gebhardt BM, Kriesel JD, Carr DJJ. The relationship between interleukin-6 and herpes simplex virus type 1: implications for behavior and immunopathology. Brain Behav. Immun. 1999;13:201–211
  10. Barber GN. The dsRNA-dependent protein kinase, PKR and cell death. Cell Death Differ. 2005;12:563–570
  11. Batnitzky S, Robinson RG, Wetzel LH, Lai CW, Halleran WJ, McMillan JH. Imaging studies in neonatal herpes simplex encephalitis. Acta Radiol. Suppl. 1986;369:197–199
  12. Bertke AS, Patel A, Imai Y, Apakupakul K, Margolis TP, Krause PR. LAT exon 1 controls HSV viral species-specific phenotypes: reactivation in the guinea pig genital model and neuron subtype-specific latent expression of LAT. J. Virol. 2009;83:10007–10015
  13. Bien CG, Bauer J. T-cells in human encephalitis. Neuromolecular Med. 2005;7:243–253
  14. Biron CA. Interferons alpha and beta as immune regulators—a new look. Immunity. 2001;661–664
  15. Boehme KW, Compton T. Innate sensing of viruses by toll-like receptors. J. Virol. 2004;78:7867–7873
  16. Boivin N, Sergerie Y, Rivest S, Boivin G. Effect of pretreatment with Toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis. J. Infect. Dis. 2008;198:664–672
  17. Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. Glia. 2003;43:281–291
  18. Bradford RD, Pettit AC, Wright PW, Mulligan MJ, Moreland LW, McLain DA, et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. 2009;
  19. Bsibsi M, Ravid R, Gveri D, van Noort JM. Broad expression of toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 2002;61:1013–1021
  20. Cantin EM, Hinton DR, Chen J, Openshaw H. Gamma interferon expression during acute and latent nervous system infection by simplex virus type 1. J. Virol. 1995;69:4898–4905
  21. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K. Nat. Immunol. 2008;9:1157–1164
  22. Carpentier PA, Begolka WS, Olson JK, Elhofy A, Karpus WJ, Miller SD. Differential activation of astrocytes by innate and adaptive immune stimuli. Glia. 2005;49:360–374
  23. Carr DJJ, Veress LA, Noisakran S, Campbell IL. Astrocyte-targeted expression of IFN-alpha-1 protects mice from acute ocular herpes simplex virus type 1 infection. J. Immunol. 1998;161:4859–4865
  24. Casrouge A, Zhang SY, Eidenschenk C, Jouanguy E, Puel A, Yang K, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science. 2006;314:308–312
  25. Chee AV, Roizman B. Herpes simplex virus 1 gene products occlude the interferon signaling pathway at multiple sites. J. Virol. 2003;78:4185–4196
  26. Cinque P, Cleator GM, Weber T, Monteyne P, Sindic CJ, van Loon AM. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J. Neurol. Neurosurg. Psychiatry. 1996;61:339–345
  27. Conrady CD, Thapa M, Wuest T, Carr DJJ. Loss of mandibular lymph node integrity is associated with an increase in sensitivity to HSV-1 infection in CD118-deficient mice. J. Immunol. 2009;182:3678–3687
  28. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 2005;174:4465–4469
  29. Dai J, Megjugorac NJ, Amrute SB, Fitzgerald-Bocarsly P. Regulation of IFN regulatory factor-7 and IFN-alpha production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells. J. Immunol. 2004;173:1535–1548
  30. Dalpke AH, Schafer MK, Frey M, Zimmermann S, Tebbe J, Weihe E, et al. Immunostimulatory CpG-DNA activates murine microglia. J. Immunol. 2002;168:4854–4863
  31. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–1421
  32. Delhaye S, Paul S, Blakqori G, Minet M, Weber F, Staeheli P, et al. Neurons produce type I interferon during viral encephalitis. Proc. Natl. Acad. Sci. U. S. A. 2006;103:7835–7840
  33. Dobson CB, Itzhaki RF. Herpes simplex virus type 1 and Alzheimer's disease. Neurobiol. Aging. 1999;20:457–465
  34. Dorman SE, Uzel G, Roesler J, Bradley JS, Bastian J, Billman G, et al. Viral infections in interferon-gamma receptor deficiency. J. Pediatr. 1999;135:640–643
  35. Doyle SE, Vaidya SA, O'Connell R, Dadgostar H, Dempsey PW, Wu TT, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 2002;17:251–263
  36. Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 2003;33:388–391
  37. Ecob-Prince MS, Rixon FJ, Preston CM, Hassan K, Kennedy PG. Reactivation in vivo and in vitro of herpes simplex virus from mouse dorsal root ganglia which contain different levels of latency-associated transcripts. J. Gen. Virol. 1993;74:995–1002
  38. Everett RD, Zafiropoulos A. Visualization by live-cell microscopy of disruption of ND10 during herpes simplex virus type 1 infection. J. Virol. 2004;78:11411–11415
  39. Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E. Preferential expression and function of toll-like receptor 3 in human astrocytes. J. Neuroimmunol. 2005;159:12–19
  40. Feldman LT, Ellison AR, Voytek CC, Yang L, Krause P, Margolis TP. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc. Natl. Acad. Sci. U. S. A. 2002;99:978–983
  41. Fischer GH, Reichman G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. 2001;166:2717–2726
  42. Fitch MT, van de Beek D. Drug insight: steroids in CNS infectious diseases—new indications for an old therapy. Nat. Clin. Pract. Neurol. 2008;4:97–104
  43. Fodor PA, Levin MJ, Weinberg A, Sandberg E, Sylman J, Tyler KL. Atypical herpes simplex virus encephalitis diagnosed by PCR amplification of viral DNA from CSF. Neurology. 1998;51:554–559
  44. Garcia-Sastre A, Biron CA. Type 1 interferons and the virus–host relationship: a lesson in détente. Science. 2006;312:879–882
  45. Halford WP, Gebhardt BM, Carr DJJ. Persistent cytokine expression in the trigeminal ganglion latently infected with herpes simplex virus type I. J. Immunol. 1996;157:3542–3549
  46. Halford WP, Gebhardt BM, Carr DJJ. Acyclovir blocks cytokine gene expression in trigeminal ganglia latently infected with herpes simplex virus type 1. Virology. 1997;238:53–63
  47. Halford WP, Weisend C, Grace J, Soboleski M, Carr DJJ, Balliet JW, et al. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol. J. 2006;3:44
  48. Harel L, Smetana Z, Prais D, Book M, Alkin M, Supaev E, et al. Presence of viremia in patients with primary herpetic gingivostomatitis. Clin. Infect. Dis. 2004;29:636–640
  49. Harle P, Sainz B, Carr DJJ, Halford WP. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/beta. Virology. 2002;293:295–304
  50. Hemmi H, Kaisho T, Takeda K, Akira S. The roles of toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J. Immunol. 2003;170:3059–3064
  51. Hjalmarrson A, Blomqvist P, Skoldenberg B. Herpes simplex encephalitis in Sweden, 1990–2001: incidence, morbidity, and mortality. Clin. Infect. Dis. 2007;45:875–880
  52. Honess RW, Roizman B. Regulation of herpes virus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J. Virol. 1974;14:8–19
  53. Ihekwaba UK, Kudesia G, McKendrick MW. Clinical features of viral meningitis in adults: significant differences in cerebrospinal fluid findings among herpes simplex virus, varicella zoster virus, and enterovirus. Clin. Infect. Dis. 2008;47:783–789
  54. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer's disease: the enemy within. J. Alzheimer's Dis. 2008;13:393–405
  55. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 2005;175:4320–4330
  56. Johnson KE, Song B, Knipe DM. Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. Virology. 2008;374:487–494
  57. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J. Exp. Med. 2000;192:219–226
  58. Kamei S, Sekizawa T, Shiota H, Mizutani T, Itoyama Y, Takasu T, et al. Evaluation of combination therapy using acyclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J. Neurol. Neurosurg. Psychiatry. 2005;76:1544–1549
  59. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 1995;28:16483–16486
  60. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, et al. Interferon-alpha induction through toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 2004;5:1061–1068
  61. Khetsuriani N, Holman RC, Anderson LJ. Burden of encephalitis-associated hospitalizations in the United States, 1988–1997. Clin. Infect. Dis. 2002;35:175–182
  62. Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J. Neurosci. Res. 2006;83:711–730
  63. Kimberlin DW. Management of HSV encephalitis in adults and neonates: diagnosis, prognosis, and treatment. Herpes. 2007;14:11–16
  64. Kleinschmidt-DeMasters BK, Gilden DH. Polymerase chain reaction as a diagnostic adjunct in herpesvirus infections of the nervous system. Brain Pathol. 2001;11:440–451
  65. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science. 2009;322:268–271
  66. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 2005;202:637–650
  67. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Hepres simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood. 2004;103:1433–1437
  68. Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, et al. Herpes simplex virus 1 interaction with toll-like receptor 2 contributes to lethal encephalitis. Proc. Natl. Acad. Sci. U. S. A. 2004;101:1315–1320
  69. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc. Natl. Acad. Sci. U. S. A. 2000;97:5684–5686
  70. Lellouch-Tubiana A, Fohlen M, Robain O, Rozenberg F. Immunocytochemical characterization of long-term persistent immune activation in human brain after herpes simplex encephalitis. Neuropath. Appl. Neurobiol. 2000;26:285–294
  71. Lin WR, Jennings R, Smith TL, Wozniak MA, Itzhaki RF. Vaccination prevents latent HSV1 infection of mouse brain. Neurobiol. Aging. 2001;22:699–703
  72. Lin R, Noyce RS, Collins SE, Everett RD, Mossman KL. The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. J. Virol. 2004;78:1675–1684
  73. Liu T, Tang Q, Hendricks RL. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J. Virol. 1996;70:264–271
  74. Losada I, Canizares A, Hellin T, Marti-Belda P, Guerrero A. [In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?] Enferm. Infecc. Microbiol. Clin. 2002;1:25–27
  75. Luker GD, Prior JL, Song J, Pica CM, Leib DA. Bioluminescence imaging reveals systemic dissemination of herpes simplex virus type 1 in the absence of interferon receptors. J. Virol. 2003;77:11082–11093
  76. Lundberg P, Ramakrishna C, Brown J, Tyszka JM, Hamamura M, Hinton DR, et al. The immune response to herpes simplex virus type 1 infection in susceptible mice is a major cause of central nervous system pathology resulting in fatal encephalitis. J. Virol. 2008;82:7078–7088
  77. Malmgaard L. Induction and regulation of IFNs during viral infections. J. Interferon Cytokine Res. 2004;24:439–454
  78. Malmgaard L, Melchjorsen J, Bowie AG, Mogensen SC, Paludan SR. Viral activation of macrophages through TLR-dependent and -independent pathways. J. Immunol. 2004;173:6890–6898
  79. Marques CP, Cheeran MC, Palmquist JM, Hu S, Urban SL, Lokensgard JR. Prolonged microglial cell activation and lymphocyte infiltration following experimental herpes encephalitis. J. Immunol. 2008;181:6417–6426
  80. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J. Exp. Med. 1999;189:521–530
  81. Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, et al. Protocol for German trial of acyclovir and corticosteroids in herpes simplex virus encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. BMC Neurol. 2008;8:40
  82. Maul GG, Guldner HH, Spivack JG. Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J. Gen. Virol. 1993;74:2679–2690
  83. McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D, et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J. Gen. Virol. 1988;69:1531–1574
  84. McGrath N, Anderson NE, Croxson MC, Powell KF. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. J. Neurol. Neurosurg. Psychiatry. 1997;63:321–326
  85. Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. Science. 2002;296:298–300
  86. Melroe GT, DeLuca NA, Knipe DM. Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J. Virol. 2004;78:8411–8420
  87. Meyding-Lamade UK, Oberlinner C, Rau PR, Seyfer S, Heiland S, Sellner J, et al. Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. J. Neurovirol. 2003;9:118–125
  88. Middleton PJ, Petric M, Kozak M, Rewcastle NB, McLachlan DR. Herpes-simplex viral genome and senile and presenile dementias of Alzheimer and Pick. Lancet. 1980;1:1038
  89. Miura S, Kurita T, Noda K, Ayabe M, Aizawa H, Taniwaki T. Symmetrical brainstem encephalitis caused by herpes simplex virus. J. Clin. Neurosci. 2009;16:589–590
  90. Mossman KL, Ashkar AA. Herpesvirus and the innate immune response. Viral Immunol. 2005;18:267–281
  91. Mossman KL, Smiley JR. Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J. Virol. 2002;76:1995–1998
  92. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264:1918–1921
  93. Musallam B, Matoth I, Wolf DG, Engelhard D, Averbuch D. Steroids for deteriorating herpes simplex virus encephalitis. Pediatr. Neurol. 2007;37:229–232
  94. Nakano A, Yamasaki R, Miyazaki S, Horiuchi N, Kunishige M, Mitsui T. Beneficial effect of steroid pulse therapy on acute viral encephalitis. Eur. Neurol. 2003;50:225–229
  95. Nicola AV, McEvoy AM, Straus SE. Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J. Virol. 2003;77:113–122
  96. Nicola AV, Hou J, Major EO, Straus SE. Herpes simplex virus type 1 enters human epidermal keratinocytes, but not neurons, via a pH-dependent endocytic pathway. J. Virol. 2005;79:7609–7619
  97. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in toll-like receptor signaling. Nat. Rev. Immunol. 2007;7:353–364
  98. Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J. Immunol. 2004;173:3916–3924
  99. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, et al. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 2007;282:7576–7581
  100. Pasieka TJ, Lu B, Crosby SD, Wylie KM, Morrison LA, Alexander DE, et al. Herpes simplex virus virion host shutoff attenuates establishment of the antiviral state. J. Virol. 2008;82:5527–5535
  101. Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches TLR-3-positive human neurons to become strong produces of beta interferon. J. Virol. 2005;79:12893–12904
  102. Preston CM. Reactivation of expression from quiescent herpes simplex virus type 1 genomes in the absence of immediate-early protein ICP0. J. Virol. 2007;81:11781–11789
  103. Raschilas F, Wolff M, Delatour F, Chaffaut C, De Broucker T, Chevret S, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin. Infect. Dis. 2002;35:254–260
  104. Rasmussen SB, Sorensen LN, Malmgaard L, Ank N, Baines JD, Chen ZJ, et al. Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J. Virol. 2007;81:13315–13342
  105. Reske A, Pollara G, Krummenacher C, Chain BM, Katz DR. Understanding HSV-1 entry glycoproteins. Rev. Med. Virol. 2007;17:205–215
  106. Rodrigues L, Nadakumar S, Bonorino C, Rouse BT, KKumaraguru U. IL-21 and IL-15 cytokine DNA augments HSV specific effector and memory CD8+ T cell response. Mol. Immunol. 2009;46:1494–1504
  107. Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001;14:778–809
  108. Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, Williams BR, et al. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 2006;80:7009–7019
  109. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity. 2000;13:539–548
  110. Sato A, Linehan MM, Iwasaki A. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2006;103:17343–17348
  111. Scumpia PO, Kelly KM, Reeves WH, Stevens BR. Double-stranded RNA signals antiviral and inflammatory programs and dysfunctional glutamate transport in TLR3-expressing astrocytes. Glia. 2005;52:153–162
  112. Sears AE, Hukkanen V, Labow MA, Levine AJ, Roizman B. Expression of the herpes simplex virus 1 alpha transinducing factor (VP16) does not induce reactivation of latent virus or prevent the establishment of latency in mice. J. Virol. 1991;65:2929–2935
  113. Sergerie Y, Boivin G, Gosselin D, Rivest S. Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice. J. Infect. Dis. 2007;196:817–825
  114. Shieh MT, Spear PG. Herpesvirus-induced cell fusion that is dependent on cell surface heparan sulfate or soluble heparin. J. Virol. 1994;68:1224–1228
  115. Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J. Cell Biol. 1992;116:1273–1281
  116. Shimeld C, Whiteland JL, Nicholls SM, Grinfeld E, Easty DL, Gao H, et al. Immune cell infiltration and persistence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1. J. Neuroimmunol. 1995;61:7–16
  117. Shimeld C, Efstathiou S, Hill T. Tracking the spread of lacZ-tagged herpes simplex virus type 1 between the eye and the nervous system of the mouse: comparison of primary and recurrent infection. J. Virol. 2001;75:5252–5262
  118. Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J. Immunol. 2005;174:1932–1937
  119. Skoldenberg B, Forsgren M, Alestig K, Bergstrom T, Burman L, Dahlqvist E, et al. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet. 1984;2:707–711
  120. Skoldenberg B, Aurelius E, Hjalmarsson A, Sabri F, Forsgren M, Andersson B, et al. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J. Neurol. 2006;253:163–179
  121. Sobel RA, Collins AB, Colvin RB, Bhan AK. The in situ cellular immune response in acute herpes simplex encephalitis. Am. J. Path. 1986;125:332–338
  122. Sorensen LN, Reinert LS, Malmgaard L, Bartholdy C, Thomsen AR, Paludan SR. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. J. Immunol. 2008;181:8604–8612
  123. Steiner I, Spivack JG, Deshmane SL, Ace CI, Preston CM. A herpes simplex virus type 1 mutant containing a nontransinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J. Virol. 1990;64:1630–1638
  124. Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, et al. Viral encephalitis: a review of diagnostic methods and guidelines for management. Eur. J. Neurol. 2005;12:331–343
  125. Superti F, Ammendolia MG, Marchetti M. New advances in anti-HSV chemotherapy. Curr. Med. Chem. 2008;15:900–911
  126. Takeda K, Akira S. TLR signaling pathways. Semin. Immunol. 2004;16:3–9
  127. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003;21:335–376
  128. Thompson RL, Preston CM, Sawtell NM. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS. Pathog. 2009;5:e1000352
  129. Tissari J, Siren J, Meri S, Julkunen I, Matikainen S. IFN-alpha enhances TLR-3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J. Immunol. 2005;174:4289–4294
  130. Town T, Jeng D, Alexopoulou L, Tan J, Flavell RA. Microglia recognize double-stranded RNA via TLR3. J. Immunol. 2006;176:3804–3812
  131. Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 2008;47:303–327
  132. Von Hoegen P. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol. Lett. 1995;47:157–162
  133. Welner RS, Pelayo R, Nagai Y, Garrett KP, Wuest TR, Carr DJJ, et al. Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection. Blood. 2008;112:3753–3761
  134. Whitley RJ. Viral encephalitis. N. Engl. J. Med. 1990;323:242–250
  135. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antivir. Res. 2006;71:141–148
  136. Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N. Engl. J. Med. 1977;297:289–294
  137. Whitley RJ, Soong SJ, Linneman C, Liu C, Pazin G, Alford CA. Herpes simplex encephalitis. Clinical assessment. JAMA. 1982;247:317–320
  138. Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N. Engl. J. Med. 1986;314:144–149
  139. Whitley RJ, Cobbs CG, Alford CA, Soong SJ, Hirsch MS, Connor JD, et al. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA. 1989;262:234–239
  140. Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci. Lett. 2007;429:95–100
  141. Wozniak MA, Frost AL, Itzhaki RF. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J. Alzheimers Dis. 2009;16:341–350
  142. WuDunn D, Spear PG. Initial interaction of herpes simplex virus with cells is binding heparan sulfate. J. Virol. 1989;63:52–58
  143. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964–973
  144. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, et al. Essential role for TIRAP in activation of the signaling cascade shared by TLR2 and TLR4. Nature. 2002;420:324–329
  145. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003;301:640–643
  146. Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, et al. Human TLR-7, -8, and -9-mediated induction of IFN-alpha/beta and -lambda is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity. 2005;23:465–478
  147. Yokota S, Yokosawa N, Kubota T, Suzutani T, Yoshida I, Miura S, et al. Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and Janus kinases during an early infection stage. J. Virol. 2001;286:119–124
  148. Zhang SY, Jouanguy E, von Bernuth H, Yang K, Abel L, Picard C, et al. Human toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol. Rev. 2007;220:225–236
  149. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007;317:1522–1527
  150. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-α/β, IFN- γ, and IFN-λ in host defense. Immunol. Rev. 2008;226:29–40
  151. Zhou A, Hassel BA, Silverman RH. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell. 1993;72:753–765
  152. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, et al. Interferon action and apoptosis are defective in mice devoid of 2′, 5′-oligoadenylate-dependent RNase L. EMBO J. 1997;16:6355–6363
  153. Zhou Y, Ye L, Wan Q, Zhou L, Wang X, Li J, et al. Activation of toll-like receptors inhibits herpes simplex virus-1 infection of human neuronal cells. J. Neurosci. Res. 2009;87:2916–2925

PII: S0165-5728(09)00359-2

doi: 10.1016/j.jneuroim.2009.09.013

Journal of Neuroimmunology
Volume 220, Issue 1 , Pages 1-9 , 30 March 2010

Article Tools

* Image Usage & Resolution